|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 7
Zeitschriftenartikel
Sams, L.; Kruger, S.; Heinemann, V.; Bararia, D.; Haebe, S.; Alig, S.; Haas, M.; Zhang, D.; Westphalen, C. B.; Ormanns, S.; Metzger, P.; Werner, J.; Weigert, O.; von Bergwelt-Baildon, M.; Rataj, F.; Kobold, S. und Boeck, S.
(2021):
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
In: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
[PDF, 1MB]
Sams, L.; Kruger, S.; Heinemann, V.; Bararia, D.; Häbe, S.; Alig, S.; Haas, M.; Zhang, D.; Westphalen, C. B.; Ormanns, S.; Metzger, P.; Werner, J.; Weigert, O.; von Bergwelt-Baildon, M.; Rataj, F.; Kobold, S. und Böck, S.
(2021):
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
In: Clinical & Translational Oncology, Bd. 23, Nr. 11: S. 2394-2401
Weigert, O.
(2017):
Translation of Next-Generation-Sequencing (NGS) into the clinics: malignant lymphomas as a paradigm.
In: Oncology Research and Treatment, Bd. 40: S. 217-218
Jurinovic, Vindi; Kridel, R.; Staiger, A. M.; Szczepanowski, M.; Horn, Heike; Dreyling, Martin; Rosenwald, Andreas; Ott, German; Klapper, Wolfram; Zelenetz, A. D.; Barr, P. M.; Friedberg, J. W.; Ansell, S.; Sehn, L. H.; Connors, J. M.; Gascoyne, R. D.; Hiddemann, Wolfgang; Unterhalt, Michael; Weinstock, D. M. und Weigert, O.
(2016):
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.
In: Blood, Bd. 128, Nr. 8: S. 1112-1120
Ferrero, S.; Pastore, A.; Scholz, C. W.; Forstpointner, R.; Pezzutto, A.; Bergmann, L.; Trümper, L.; Finke, J.; Keller, U.; Ghione, P.; Passera, R.; Hiddemann, W.; Weigert, O.; Unterhalt, M. und Dreyling, M.
(2016):
Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial.
In: Leukemia, Bd. 30, Nr. 4: S. 984-987
Weigert, O.
(2016):
Molecular risk stratification for follicular lymphoma.
In: Oncology Research and Treatment, Bd. 39: S. 301
Pastore, A.; Jurinovic, Vindi; Kridel, R.; Hoster, Eva; Staiger, A. M.; Szczepanowski, M.; Pott, Christiane; Kopp, N.; Murakami, M.; Horn, Heike; Leich, E.; Moccia, A. A.; Mottok, A.; Sunkavalli, A.; van Hummelen, P.; Ducar, M.; Ennishi, D.; Shulha, H. P.; Hother, C.; Connors, J. M.; Sehn, L. H.; Dreyling, Martin; Neuberg, D.; Moller, P.; Feller, A. C.; Hansmann, Martin-Leo; Stein, H.; Rosenwald, Andreas; Ott, German; Klapper, Wolfram; Unterhalt, Michael; Hiddemann, Wolfgang; Gascoyne, R. D.; Weinstock, D. M. und Weigert, O.
(2015):
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
In: Lancet Oncology, Bd. 16, Nr. 9: S. 1111-1122